Upcoming Events
  1. ***UPDATED*** ALTG Members’ Meeting, Sydney NSW

    November 24
  2. ***UPDATED*** 2017 ALTG Lung Cancer Symposium, Sydney NSW

    November 24 @ 9:00 am - November 25 @ 5:00 pm UTC+10

Who’s Who on the Management Advisory Committee

The Management Advisory Committee (MAC) is responsible for overseeing the affairs of the ALTG. MAC roles include President, Secretary, Treasurer and representatives of different ALTG craft groups. We asked some of our MAC members to tell us a little about themselves and their involvement with the ALTG.

Cameron Hunter – Treasurer 

Please tell us a little about yourself and how you came to be involved with the ALTG.Cameron-Hunter-150px

I trained in the UK and was a member of the Papworth Hospital Lung Cancer team for 7 years, as well as developing lung cancer services at the local district hospital.  I moved to Hobart in 2007 and further developed services for lung cancer there. Initially I became involved in the ALTG as the Respiratory Physician representative on the MAC and now I’m the Treasurer.

What is it about being a member of the MAC that you find most interesting?

Being involved in the development and generation of ideas for research into lung cancer; hearing the results as the trials develop; and especially the friendly and supportive interactions with the others in the group.

How would you like to see the ALTG develop over time?

I’d like to see us with a wide portfolio of trials across all the disciplines involved in lung cancer. I would like to see the ALTG recognised as the main “go to” place for lung cancer research, with high public recognition of the group and hence lung cancer research.

Craig Lewis – Medical Oncology Representative

Please tell us a little about yourself and how you came to be involved with the ALTG.CRL photo

I’m a medical oncologist at Prince of Wales Hospital in Sydney. I’ve treated patients with lung cancer for over 20 years and participated in many clinical trials in this patient group. I was previously a member of the ALCC and was involved in the early discussions towards the development of the ALTG concept. Professor Kwun Fong roped me in as a medical oncologist with an interest and I haven’t stopped moving with the momentum since then!

What is it about being a member of the MAC that you find most interesting?

Participating in exciting and vibrant discussions with colleagues with a shared interest lung cancer in Australia, and meeting and collaborating with some truly amazing consumer reps in the MAC and the trials group.

How would you like to see the ALTG develop over time?

To continue to develop a broad range of clinical trials specific to Australia across all facets of lung cancer clinical and translational research, to foster collaboration with the other world-wide lung cancer trials groups, to broaden representation of all craft groups involved in lung cancer care, and to mentor and encourage young cancer doctors to focus on lung cancer care and trials as their key area of interest – now is an exciting time to be involved!

Shankar Siva – Radiation Oncology Representative

Please tell us a little about yourself and how you came to join the ALTG.Shankar-Siva-178px

I am a radiation oncologist and clinical researcher at the Peter MacCallum Cancer Centre. I have a special interest in stereotactic ablative body radiotherapy (SABR) and co-ordinate the program at the Peter Mac.  I was “tapped on the shoulder” to join the MAC early during my PhD studies in 2012 by my mentor Professor David Ball and have been serving ever since.

What is it about being a member of the CAP that you find most interesting?

With research it is easy to become engrossed in your own particular niche area of interest. I love being involved in the MAC because it gives me a global perspective of the direction of lung cancer trials in the region.

How would you like to see the ALTG develop over time?

I would like to see the ALTG engage our neighbour Asian countries in collaboration and truly embrace our “Australasian” moniker. Additionally, I feel medical oncologists are leading the way in engagement within the ALTG and ideally we would see growth in the representation of all the disciplines involved in the care of lung cancer patients.